UKIPO rejects Novartis’s TM opposition attempt

Switzerland-based Novartis has failed to convince the UK Intellectual Property Office (IPO) that a trademark applied-for by Boston Healthcare should not be registered.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Novartis and others in ‘unprecedented’ COVID-19 partnership

27 March 2020 A consortium of life sciences companies including Novartis, Bristol Myers Squibb and GSK have united to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19.

Big Pharma

Novartis sues Chinese firm over attempts to make generic heart failure drug

30 September 2021 Pharma giant Novartis has filed a patent suit against Crystal Pharmaceuticals after the rival sought to create a generic version of its heart failure drug Entresto.

article

UKIPO appoints permanent chief executive

13 December 2022 Interim CEO becomes permanent | Appointee “brings broad leadership experience and deep knowledge of the IPO” | Appointment “concludes a period of change at IPO”.

More on this story

Americas

Novartis and others in ‘unprecedented’ COVID-19 partnership

Big Pharma

Novartis sues Chinese firm over attempts to make generic heart failure drug

30 September 2021 Pharma giant Novartis has filed a patent suit against Crystal Pharmaceuticals after the rival sought to create a generic version of its heart failure drug Entresto.

article

UKIPO appoints permanent chief executive

13 December 2022 Interim CEO becomes permanent | Appointee “brings broad leadership experience and deep knowledge of the IPO” | Appointment “concludes a period of change at IPO”.

More on this story

Americas

Novartis and others in ‘unprecedented’ COVID-19 partnership

Big Pharma

Novartis sues Chinese firm over attempts to make generic heart failure drug

30 September 2021 Pharma giant Novartis has filed a patent suit against Crystal Pharmaceuticals after the rival sought to create a generic version of its heart failure drug Entresto.

article

UKIPO appoints permanent chief executive

13 December 2022 Interim CEO becomes permanent | Appointee “brings broad leadership experience and deep knowledge of the IPO” | Appointment “concludes a period of change at IPO”.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

UKIPO rejects Novartis’s TM opposition attempt

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features